Trevi Therapeutics (TRVI) Tops Q4 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
• Waste stocks ride AI and healthcare boom as CLH surges 27%